# Impact     BioMedical, INC. (IBO) · Edgar & Edgarette company card

> Impact     BioMedical (IBO) saw revenue fall 36.0% in FY2025 to $0 million, operating margin -13381% against a -3.8% median for pharmaceutical preparations, equity 72.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1834105 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/IBO) · [JSON](https://www.pops4.com/boards/company/IBO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $32,000 |
| Revenue growth, 1 year | -36.0% |
| Revenue growth per year | -13.8% |
| Operating margin | -13381.3% (prior year -6808.0%) |
| Net margin | -37093.8% |
| Operating cash flow | −$2M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $3,000 |
| Long-term debt | — |
| Total assets | $17M |
| Total equity | $13M |
| Equity ÷ assets | 72.4% |
| Return on equity | -94.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -4.05 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$1.9M in FY2025); operating loss: a margin of -13381.3% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $32K (FY2025). Experience: revenue down 36.0% on the year, down 13.8% a year over 3 years; operating margin -13381.3%, down from -6808.0%. Soundness: equity 72.4% of assets, return on equity -94.1%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $18K and $32K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -13381.3% against a -3.8% median; growth -36.0% against 13.7%.

Range logged 2026-09-20, receipt deea93264feee1c0, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-11-03 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1834105/000149315226049727/0001493152-26-049727-index.htm)
- 8-K · filed 2026-10-09 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1834105/000149315226046572/0001493152-26-046572-index.htm)
- 8-K · filed 2026-09-17 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1834105/000149315226042975/0001493152-26-042975-index.htm)
- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1834105/000149315226042635/0001493152-26-042635-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1834105/000149315226036601/0001493152-26-036601-index.htm)
- 10-Q · filed 2026-05-12 · [filing](https://www.sec.gov/Archives/edgar/data/1834105/000149315226022512/0001493152-26-022512-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001834105.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1834105

## Cite

POPS4, Edgar & Edgarette: Impact     BioMedical, INC. (IBO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/IBO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.